LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Integrated Analyses Offer Molecular Insights to Tumor Subtypes

By LabMedica International staff writers
Posted on 19 Jul 2018
Image: A histopathology of mixed germ cell tumor of the testes demonstrating the high-grade cytology, typical for embryonal carcinoma (Photo courtesy of Nephron).
Image: A histopathology of mixed germ cell tumor of the testes demonstrating the high-grade cytology, typical for embryonal carcinoma (Photo courtesy of Nephron).
The most common malignancy of young adult males of European descent are testicular germ cell tumors (TGCTs) of the type derived from germ cell neoplasia in situ (GCNIS). There are two major histologic types: pure classic seminoma and nonseminomatous germ cell tumors (NSGCTs).

Seminoma often has more indolent behavior, while NSGCT tends to occur at younger ages and confer higher mortality. TGCTs are now highly treatable, and overall relative survival of men with TGCTs exceeds 95%; however, survivors can experience devastating late effects of treatment.

An extensive team of scientists collaborating with those at University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) studied 137 primary testicular germ cell tumors (TGCTs) using high-dimensional assays of genomic, epigenomic, transcriptomic, and proteomic features. The median age of diagnosis was 31 years, with a range of 14 to 67. Patient tumor histology was classified according to a consensus of expert pathologists. Molecular and genomic data were collected using reverse phase protein arrays (RPPAs), whole-exome DNA sequencing, RNA-seq, miRNA sequencing, DNA methylation arrays, and SNP arrays for copy number analysis.

The team reported that as expected, the 72 seminomas in this set clustered apart from the non-seminomatous tumors, based on these molecular data. They saw relatively limited mutation frequencies across most of the histological subtypes. Just three genes, KIT, KRAS, and NRAS, were significantly mutated in the TGCTs, and those recurrent mutations were limited to the seminoma subtype. Within seminomas, DNA methylation and immune infiltration differences also tended to coincide with the presence or absence of KIT gene mutations. Still other mutation frequency, ploidy, DNA methylation, and/or miRNA expression shifts corresponded with the remaining non-seminomatous subtypes.

In teratoma and yolk sac tumors, the group saw enhanced expression of a miRNA called miR-375 that is typically found at low levels in blood samples from healthy individuals. On the other hand, the embyronal carcinomas had higher-than-usual expression of miR-19 and other miRNAs, they noted, and were marked by DNA methylation at non-canonical cytosine sites.

The authors concluded the new TGCT molecular profiles afforded a more complete view of previously articulated hypotheses, provide additional insights into mechanisms of TGCT tumorigenesis, and identify possible new approaches to the treatment of TGCTs. Katherine Hoadley, PhD, is an assistant professor in Cancer Genetics and senior author of the study, said, “Integration of tumor characteristics and genomic and epigenomics data revealed distinctive molecular landscapes of TGCT histologic types, and identified previously unappreciated diversity within seminomas.” The study was published on June 12, 2018, in the journal Cell Reports.

Related Links:
University of North Carolina at Chapel Hill

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more